K Pharma,Inc. (TYO:4896)
Japan · Delayed Price · Currency is JPY 763.00
+3.00 (0.39%)
Aug 27, 2026, 1:54 PM JST
K Pharma,Inc. Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,364 | 2,791 | 2,268 | 3,266 | 1,336 | 188 |
Cash & Short-Term Investments | 2,364 | 2,791 | 2,268 | 3,266 | 1,336 | 188 |
Cash Growth | 28.76% | 23.06% | -30.56% | 144.46% | 610.64% | - |
Inventory | 7 | 11 | 5 | 10 | 10 | 9 |
Prepaid Expenses | 109 | 57 | 39 | 31 | 22 | 6 |
Other Current Assets | 26 | 31 | 36 | 1 | 2 | 1 |
Total Current Assets | 2,506 | 2,890 | 2,348 | 3,308 | 1,370 | 204 |
Long-Term Investments | 61 | 48 | 4 | 4 | 3 | 1 |
Other Long-Term Assets | - | 1 | 1 | 1 | 1 | - |
Total Assets | 2,567 | 2,939 | 2,353 | 3,313 | 1,374 | 205 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 9 | 8 | 10 | 11 | 10 | 2 |
Accrued Expenses | 64 | 69 | 48 | 30 | 21 | 17 |
Current Income Taxes Payable | 6 | 19 | 1 | 76 | 1 | - |
Other Current Liabilities | 5 | 5 | 4 | 61 | 1 | 4 |
Total Current Liabilities | 134 | 101 | 63 | 178 | 33 | 23 |
Long-Term Debt | 1,587 | 1,500 | - | - | - | - |
Other Long-Term Liabilities | 73 | 73 | 32 | 31 | 5 | 4 |
Total Liabilities | 1,794 | 1,674 | 95 | 209 | 38 | 27 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 10 | 10 | 100 | 854 | 100 | 100 |
Additional Paid-In Capital | 1,255 | 2,248 | 3,004 | 3,003 | 2,249 | 699 |
Retained Earnings | -492 | -993 | -846 | -752 | -1,012 | -620 |
Comprehensive Income & Other | - | - | - | -1 | -1 | -1 |
Shareholders' Equity | 773 | 1,265 | 2,258 | 3,104 | 1,336 | 178 |
Total Liabilities & Equity | 2,567 | 2,939 | 2,353 | 3,313 | 1,374 | 205 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,637 | 1,500 | - | - | - | - |
Net Cash (Debt) | 727 | 1,291 | 2,268 | 3,266 | 1,336 | 188 |
Net Cash Growth | -60.40% | -43.08% | -30.56% | 144.46% | 610.64% | - |
Net Cash Per Share | 62.60 | 111.25 | 195.44 | 289.79 | 143.18 | 24.73 |
Filing Date Shares Outstanding | 11.62 | 11.61 | 11.6 | 11.32 | 9.33 | 7.6 |
Total Common Shares Outstanding | 11.62 | 11.61 | 11.6 | 11.32 | 9.33 | 7.6 |
Working Capital | 2,372 | 2,789 | 2,285 | 3,130 | 1,337 | 181 |
Book Value Per Share | 66.51 | 109.00 | 194.58 | 274.20 | 143.18 | 23.42 |
Tangible Book Value | 773 | 1,265 | 2,258 | 3,104 | 1,336 | 178 |
Tangible Book Value Per Share | 66.51 | 109.00 | 194.58 | 274.20 | 143.18 | 23.42 |